🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Ralinepag, Ralinepag, Ralinepag, Ralinepag

    United Therapeutics Europe Ltd

    Pulmonary arterial hypertension (PAH)

    phase 3 small molecule active

    1 trial

  2. Raltegravir

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  3. Ramucirumab

    Eli Lilly and Company

    Urothelial Carcinoma

    phase 3 small molecule completed

    1 trial

  4. Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee osteoarthritis.

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial

  5. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  6. Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

    Sanofi-aventis Healthcare Pty Ltd

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  7. Ranibizumab

    Hoffmann-La Roche

    Neovascular Age-related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  8. Ravulizumab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  9. Ravulizumab

    Alexion Europe SAS

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 mab completed

    2 trials

  10. Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  11. Realgar-Indigo naturalis formula

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  12. Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  13. Recombinant Factor VIII (BAY81-8973)

    Bayer HealthCare AG

    Blood Coagulation Disorders

    phase 3 mab completed

    1 trial

  14. Recombinant Factor VIIa

    United Therapeutics Europe Ltd

    Burns

    phase 3 small molecule completed

    1 trial

  15. Recombinant Factor VIIa BI (rFVIIa BI)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  16. Recombinant Human Albumin Injection

    The First People's Hospital of Lianyungang

    Hepatic Ascites

    phase 3 mab completed

    2 trials

  17. Recombinant Human Thrombopoietin (rhTPO)

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  18. Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papillomavirus Infection

    phase 3 mab active

    1 trial

  19. Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  20. Recombinant factor IX

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  21. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Acute Stroke

    phase 3 small molecule active

    1 trial

  22. Recommended treatment schedule

    Prime Medicine

    COVID-19

    phase 3 small molecule terminated

    1 trial

  23. Recovery Management Checkups (RMC)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 3 other completed

    1 trial

  24. Reducing Antibiotics treatment duration

    United Therapeutics Europe Ltd

    Ventilator Associated Pneumonia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources